25B-NBOMe

25B-NBOMe is a psychedelic hallucinogen that is used in biochemistry research for mapping the usage of the 5-HT2A receptor; it is also sometimes used for recreational purposes. A derivative of the phenethylamine 2C-B, it is part of the NBOMe series of N-benzyl derivatives.

History

25B-NBOMe was discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5-HT2A receptor. Anecdotal reports from users suggest that compared with 2C-B, 25B-NBOMe can be more potent, has a longer duration, and has a similar safety profile.

Pharmacology

25B-NBOMe is a phenethylamine with a methoxy group at the 2 and 5 positions of the benzene ring, and a nitrogen atom at the 1 position. The nitrogen atom is part of a N-benzyl group, which is substituted at its terminal nitrogen atom by a 2-methoxybenzyl (BnOMe) group.

Effects

The effects of 25B-NBOMe can vary by dose, and the onset, peak, and duration can vary depending on the method of administration. Effects can include intense hallucinations, distorted perception of time, and feelings of euphoria. It can also cause vasoconstriction and increased heart rate, which can lead to serious medical emergencies.

Legal status

The legal status of 25B-NBOMe varies by country and can change over time. As of 2013, it is a controlled substance in many countries, including the United States, Australia, and the United Kingdom.

See also

• 25I-NBOMe
• 25C-NBOMe
• 2C-B
• Psychedelic drug
• Hallucinogen

25B-NBOMe Resources
Latest articles Most recent articles Ongoing trials	Wikipedia